ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Operating Cash Flow
Cash generated by the company's core business operations during the period.
Operating Cash Flow history
Currency unavailable · from the cash flow
No Operating Cash Flow data reported for this period type.
Operating Cash Flow vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $182.35M USD | +1.0% | +13.6% | 254.0% | |
| LTM Mar 2026 | $156.42M USD | +50.4% | +7.2% | 3877.5% | |
| LTM Mar 2026 | $146.82M USD | -311.1% | — | 457.7% | |
| LTM Mar 2026 | $65.57M USD | — | +3.0% | 7115.1% | |
| LTM Mar 2026 | $58.57M USD | -34.4% | — | 129.2% | |
| LTM Mar 2026 | €48.04M EUR | +29.6% | -9.5% | 357.4% | |
| FY2025 | $41.13M USD | — | — | 220.9% | |
| LTM Mar 2026 | $20.57M USD | +10.2% | +14.1% | — | |
| LTM Mar 2026 | $8.28M USD | +107.9% | -14.1% | 10.4% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | +10.2% | +5.1% | 305.7% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.